Drug Information

Drug (ID: DG01812) and It's Reported Resistant Information

• Name: Anisomycin
• Synonyms: Anisomycin; 22862-76-6; Flagecidin; (-)-Anisomycin; TCMDC-125504; (2R,3S,4S)-4-hydroxy-2-(4-methoxybenzyl)pyrrolidin-3-yl acetate; Upjohn 204t3; UNII-6C74YM2NGI; (2R,3S,4S)-2-(p-Methoxybenzyl)-3,4-pyrrolidinediol 3-acetate; NSC76712; NSC 76712; NSC-76712; Anisomycin from Streptomyces griseolus; 2-(p-Methoxybenzyl)-3,4-pyrrolidinediol 3-acetate; 6C74YM2NGI; 1,4,5-Trideoxy-1,4-imino-5-(p-methoxyphenyl)-D-xylo-pentitol 3-acetate; [(2R,3S,4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl] acetate; MLS001066392; Anisomycin,streptomyces griseolus; CHEBI:338412; (2R,3S,4S)-2-[(4-Methoxyphenyl)methyl]-3,4-pyrrolidinediol 3-acetate; MFCD00077650; SMR000471874; 3,4-Pyrrolidinediol, 2-[(4-methoxyphenyl)methyl]-, 3-acetate,(2R,3S,4S)-; 2-p-Methoxyphenylmethyl-3-acetoxy-4-hydroxypyrrolidine; (2R,3S,4S)-2-((4-Methoxyphenyl)methyl)-3,4-pyrrolidinediol 3-acetate; 3,4-Pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2R,3S,4S)-; 3,4-Pyrrolidinediol, 2-[(4-methoxyphenyl)methyl]-, 3-acetate, (2R,3S,4S)-; ANM; Antibiotic PA-106; NSC 147340; SR-01000597397; GNF-Pf-4549; Wuningmeisu C; (2R,3S,4S)-2-(p-Methoxyphenylmethyl)-3-acetoxy-4-hydroxypyrrolidine; 6185-RBK-10; (-) Anisomycin; EINECS 245-269-7; BRN 0020705; Spectrum_001534; AI3-50846; Prestwick3_000412; Spectrum2_000632; Spectrum4_000748; Spectrum5_001495; 2-[(4-Methoxyphenyl)methyl]-3,4-pyrrolidinediol 3-acetate; CBiol_002064; BSPBio_000364; BSPBio_001436; KBioGR_001076; KBioSS_002014; ZINC954; 5-21-05-00523 (Beilstein Handbook Reference); DivK1c_000855; SPECTRUM1503906; SPBio_000624; (2R,3S,4S)-2-(4-Methoxybenzyl)-3,4-pyrrolidinediol-3-acetate; BPBio1_000402; CHEMBL423192; cid_253602; SCHEMBL2270183; DTXSID5040966; BDBM63919; HMS502K17; KBio1_000855; KBio2_002014; KBio2_004582; KBio2_007150; NINDS_000855; Bio1_000350; Bio1_000839; Bio1_001328; HMS1922K06; HMS2096C06; HMS2231E05; HMS3267L11; HMS3414L17; HMS3678L15; CCG-39185; (2R,3S,4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl acetate; AKOS015916532; CS-4981; DB07374; SDCCGMLS-0066810.P001; 3,4-Pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2R-(2alpha,3alpha,4beta))-; IDI1_000855; QTL1_000009; NCGC00025097-02; NCGC00025097-03; NCGC00025097-04; 3,4-Pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2R-(2-alpha,3-alpha,4-beta))-; AC-35125; AS-44380; HY-18982; NCI60_041689; AB00513833; B6674; A-7940; A927918; Anisomycin, Antibiotic for Culture Media Use Only; Q378498; SR-01000597397-1; SR-01000597397-3; BRD-K91370081-001-04-6; BRD-K91370081-001-17-8; 3, 2-(p-methoxybenzyl)-, 3-acetate, (2S,3R,4R)-; Anisomycin from Streptomyces griseolus, >=98% (HPLC), solid; (2R,3S,4S)-2-(4-Methoxybenzyl)-3,4-pyrrolidinediol 3-Acetate; (2R,3S,4S)-4-Hydroxy-2-(4-methoxybenzyl)-3-pyrrolidinyl acetate; acetic acid [(2R,3S,4S)-4-hydroxy-2-p-anisyl-pyrrolidin-3-yl] ester; [(2R,3S,4S)-2-[(4-methoxyphenyl)methyl]-4-oxidanyl-pyrrolidin-3-yl] ethanoate; 3, 2-[(4-methoxyphenyl)methyl]-, 3-acetate, [2S-(2.alpha.,3.alpha.,4.beta.)]-; 3,4-Pyrrolidinediol, 2-(p-methoxybenzyl)-, 3-acetate, (2S,3R,4R)- (8CI); acetic acid [(2R,3S,4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]-3-pyrrolidinyl] ester; [[4-[2-[[(3-Ethyl-2,5-dihydro-4-methyl-2-oxo-1H-pyrrol-1-yl)carbonyl]amino]ethyl]phenyl]sulfonyl]carbamicacidethylester; 11023-48-6
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Ovarian cancer [ICD-11: 2C73]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: 5
• IsoSMILES: CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O
• InChI: InChI=1S/C14H19NO4/c1-9(16)19-14-12(15-8-13(14)17)7-10-3-5-11(18-2)6-4-10/h3-6,12-15,17H,7-8H2,1-2H3/t12-,13+,14+/m1/s1
• InChIKey: YKJYKKNCCRKFSL-RDBSUJKOSA-N
• PubChem CID: 253602
• DrugBank ID: DB07374

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Ovarian cancer [ICD-11: 2C73]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Maternally expressed 3 (MEG3) [1]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Ovarian cancer [ICD-11: 2C73.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Primary human ovarian cancer stem cells; N.A.; Homo sapiens (Human); N.A.
• In Vivo Model: Female BALB/c nude mice xenograft model; Mus musculus
• Experiment for Molecule Alteration: Microarray assay; Luciferase assay; Overexpression assay
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: Anisomycin inhibited the activation downstream of the Notch1 pathway by attenuating the molecular sponge effect of the LncRNA Meg3/miR 421/PDGFRA axis, ultimately inhibiting angiogenesis, proliferation and invasion in ovarian cancer cells.

References

• Ref 1: LncRNA MEG3 contributes to adenosine-induced cytotoxicity in hepatoma HepG2 cells by downregulated ILF3 and autophagy inhibition via regulation PI3K-AKT-mTOR and beclin-1 signaling pathwayJ Cell Biochem. 2019 Oct;120(10):18172-18185. doi: 10.1002/jcb.29123. Epub 2019 May 29.